A novel risk classification score for malignant ureteral obstruction: a multicenter prospective validation study.

Area of Science:

• Oncology
• Urology
• Medical Prognostics

Background:

• Malignant ureteral obstruction (MUO) indicates poor prognosis, but survival times vary widely.
• No established risk classification score exists for MUO patients.
• Accurate prognostic tools are needed to guide treatment strategies.

Purpose of the Study:

• To validate a novel risk classification score, PLaCT (Primary site, Laterality, serum Creatinine level, and Treatment for primary site), for predicting overall survival in a large cohort of MUO patients.
• To assess the score's effectiveness in stratifying patients into distinct risk groups.
• To evaluate ureteral stent failure-free survival across different risk groups.

Main Methods:

• A prospective, multicenter diagnostic/prognostic study enrolled 300 patients with MUO from 21 primary sites.
• Patients were categorized into good, intermediate, and poor risk groups using the PLaCT score.
• Overall survival and ureteral stent failure-free survival were prospectively monitored and compared between groups.

Main Results:

• Median survival times were 406 days (good), 221 days (intermediate), and 77 days (poor) (P < 0.0001).
• Median ureteral stent failure-free survival times were 385 days (good), 183 days (intermediate), and 57 days (poor) (P < 0.0001).
• The PLaCT score demonstrated significant stratification capabilities for both survival and stent patency.

Conclusions:

• The PLaCT risk score effectively categorizes MUO patients into three distinct prognostic groups.
• This score aids physicians in establishing prognosis and tailoring treatment strategies for cancer patients with MUO.
• The PLaCT score shows potential for improving patient management and outcomes in malignant ureteral obstruction.